LONA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

LeonaBio, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 7.06 USD
-4.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -11.0% below the Trend Line and sits at 33.1% of its 52-week range. The latest completed week returned -4.5%, after a -20.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 30 out of 100
Latest Close 7.06 USD 31 Jul 2026
1W Return -4.5% latest completed week
4W Return -20.4% short-term follow-through
12W Return -29.7% quarterly tape
Trend Breadth 92.3% 48 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.5% Latest completed week; four-week move -20.4%. Indicator stack 51/33 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.28% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 22 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -11.0% below the Trend Line and sits at 33.1% of its 52-week range. The latest completed week returned -4.5%, after a -20.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.65

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -20.4% over four weeks, -29.7% over 12 weeks, and 90.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.5%
4W-20.4%
12W-29.7%
26W48.9%
52W90.7%
Active trend streak0 weeks
Active weeks in one year48
Trend breadth92.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.87Latest activity-pressure read.
Pressure change-12.4%Four-week change in activity pressure.
Leadership1.76Latest relative-leadership reading.
RS change-93.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality64/100Profitability and accounting quality. Underlying universe rank 37; rank 1 is best.
Momentum66/100Medium-term price momentum. Underlying universe rank 35; rank 1 is best.
Growth66/100Revenue and earnings growth. Underlying universe rank 35; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-139.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-184.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 22 relevant articles.

4 positive · 15 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-50.3%Distance below the 52-week high.
13-week volatility11.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+44.5%Week of 13 Mar.
Worst week-24.8%Week of 17 Jul.
Latest week-4.5%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses2
Sharp losses12
Recent vol11.1%13-week weekly-return volatility.
Base vol16.5%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew14.5% / -7.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape37/100

Trend, activity pressure, participation, and risk combine to a 37/100 tape read.

 Indicator analysis68/100

Latest 12-week confirmation: trend 11/12, activity pressure 5/12, relative leadership 12/12.

Activity pressure 0.50; No reversal markers Next-Week ExpectancyNegative 39.28%

Next-week expectancy is negative with a 39.28% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors69/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 44; Small Cap Core rank 43 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 22 relevant articles.

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20267.06 USD-4.5%7.93 USD12.56 USD-0.871.7673.5KOff
24 Jul 20267.39 USD2.4%7.93 USD12.71 USD-0.827.8354.6KOn
17 Jul 20267.22 USD-24.8%7.93 USD12.84 USD-0.734.21471.4KOn
10 Jul 20269.60 USD8.2%7.92 USD13.00 USD-0.7733.59171.4KOn
3 Jul 20268.87 USD-5.6%7.73 USD13.13 USD-0.7726.9986.5KOn
26 Jun 20269.40 USD14.9%7.57 USD13.25 USD-0.6437.44112.1KOn
19 Jun 20268.18 USD-2.0%7.40 USD13.38 USD-0.3316.0453.7KOn
12 Jun 20268.35 USD1.6%7.28 USD13.52 USD0.1222.9374.6KOn
5 Jun 20268.22 USD-13.8%7.15 USD13.66 USD0.5525.29112.5KOn
29 May 20269.54 USD-7.6%7.00 USD13.81 USD0.9140.26155.0KOn
22 May 202610.33 USD-8.3%6.83 USD13.94 USD0.9758.55288.5KOn
15 May 202611.26 USD12.2%6.62 USD14.05 USD0.8778.31194.4KOn
8 May 202610.04 USD13.8%6.36 USD14.16 USD0.7462.20193.5KOn
1 May 20268.82 USD5.9%6.15 USD14.28 USD0.7153.34110.4KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.